



### Jacobus – Recall of Ruzurgi® (amifampridine)

- On September 13, 2021, **Jacobus announced** a voluntary, consumer level recall of three lots of **Ruzurgi (amifampridine)** because the tablets have been found to be contaminated with yeast, mold, and aerobic bacteria based on laboratory test results.
  - Other Ruzurgi tablets are not being recalled and are available for patients to use.
- Ruzurgi was distributed to specialty pharmacies and physicians from June 1, 2021 through August 30, 2021:

Product Description	NDC #	Control# (Expiration Date)
Ruzurgi (amifampridine) 10 mg tablets, 100 count bottle	49938-110-01	18038 (3/2023); 18039 (3/2023); 18079 (5/2023)

- Ruzurgi is approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.
- Oral products heavily contaminated with yeast, mold, and aerobic bacteria may result in serious and life-threatening infections. The use of the defective product in patients with underlying immunosuppressive conditions such as LEMS increases the concern for serious infections.
- To date, Jacobus has not received reports of any adverse events or identifiable safety concerns attributed to the recalled lots.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled Ruzurgi tablets.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Jacobus at **1-609-799-8221, ext. 2120** for further information regarding this recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.